Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-009: lenvatinib with or without pembrolizumab versus standard chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma after platinum and PD-1/PD-L1 therapy
MOH_2020-06-14_008950Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- May 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab and lenvatinib in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by Merck & Co. Started May 2020; status: recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on MOH_2020-06-14_008950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-06-14_008950.